38 results about "Collagen ii" patented technology

A resorbable extracelluar matrix for reconstruction of cartilage tissue includes a mixture of collagen I and collagen II in a respective ratio of from about 1:19 to 19:1. The matrix can be utilized as a scaffold implant for vertebral or meniscal cartilage regeneration.

A resorbable extracellular matrix for reconstruction of cartilage tissue includes a purified collagen II derived from natural cartilage tissue from which non-collagen proteins have been removed. The matrix can be utilized as a scaffold implant for meniscal or vertebral cartilage regeneration.

The invention discloses a recombinant human collagen and a production method thereof and belongs to the technical field of genetic engineering. The structure of the recombinant human collagen is a single-chain structure; the basic repeating unit is gergapgfrgpagpngipgekgpagergap which is a human collagen III peptide fragment; the terminal sequence is GPPGPCCGGG which is a human collagen II peptide fragment. The production method of the recombinant human collagen comprises the following steps of: constructing escherichia coli genetically engineered bacterium; fermenting and cultivating the escherichia coli genetically engineered bacterium; inducing and expressing the recombinant human collagent; and purifying the recombinant human collagen. According to the recombinant human collagen and the production method thereof disclosed by the invention, the escherichia coli expression system is adopted for being amplified in a large-scale manner, the production cost is low and the yield is high.

The present invention relates to antibodies against human collagen II, polypeptides and polynucleotides encoding human collagen II antibodies or fragments thereof, and methods of making and using the foregoing.

The present invention relates to antibodies against human collagen II, polypeptides and polynucleotides encoding human collagen II antibodies or fragments thereof, and methods of making and using the foregoing.

A resorbable extracelluar matrix for reconstruction of cartilage tissue includes a mixture of collagen I and collagen II in a respective ratio of from about 1:19 to 19:1. The matrix can be utilized as a scaffold implant for vertebral or meniscal cartilage regeneration.

The invention relates to the field of bioengineering, in particular to a preparation method of industrialized non-denaturing collagen II. The preparation method comprises the steps of cartilage pretreatment, alkali liquor extraction, separation, drying and enzymolysis. Most impurities such as soluble protein, fat, chondroitin sulfate and hyaluronic acid in cartilage are removed by low-temperaturealkali liquor extraction, subsequent separation and drying of insoluble non-denatured collagen II powder as well as extraction and refining of soluble non-denaturing collagen II in the enzymolysis step are facilitated, and salting out, dialysis and other operation in the enzymolysis step in the conventional method can be omitted; the preparation method has simple steps and short working hours, ismore beneficial to industrial production, avoids production of a large amount of waste water, and has potential market value accordingly.

The invention discloses a recombinant human collagen and a production method thereof and belongs to the technical field of genetic engineering. The structure of the recombinant human collagen is a single-chain structure; the basic repeating unit is gergapgfrgpagpngipgekgpagergap which is a human collagen III peptide fragment; the terminal sequence is GPPGPCCGGG which is a human collagen II peptide fragment. The production method of the recombinant human collagen comprises the following steps of: constructing escherichia coli genetically engineered bacterium; fermenting and cultivating the escherichia coli genetically engineered bacterium; inducing and expressing the recombinant human collagent; and purifying the recombinant human collagen. According to the recombinant human collagen and the production method thereof disclosed by the invention, the escherichia coli expression system is adopted for being amplified in a large-scale manner, the production cost is low and the yield is high.

The present invention provides a composition comprising an antibody or fragment thereof against oxidised Collagen II (CII) in which the antibody or fragment thereof is conjugated to a pharmaceutically active moiety. The invention also provides a composition comprising an antibody or fragment thereof against oxidised Collagen II (CII) and a detectable label. The invention further provides the use of such compositions in medicine, in particular for the treatment of an arthropathy, and in methods of diagnosis.

The invention relates to a kind of laminated gradient composite scaffold material based on the bionic structure and its preparation method. The said material has three or more layers of porous structure, comprising of hyaluronic acid, PLGA, PLA, collagen II and nano-hydroxyapatite (nano-HA) , beta- tricalcium phosphate ( beta-TCP). The upper layer is made by collagen II / hyaluronic acid or PLGA and PLA imitating the cartilage layer. With the counterfeit the calcified cartilage layer in the middle, it is one layer or multi- sublayer, made by nano-HA or beta-TCP with collagen II / hyaluronic acid or PLGA and PLA; the bottom is made of nano-HA or beta-TCP with collagen II or PLGA and PLA. From top to bottom, the content of inorganic material increases in its layers, about 0 to 60 mass percent of layers. The aperture of the scaffold material is 50 to 450 micron, with 70 to 93 percent porosity. The scaffold material made by this invention has an adjustable degradation rate, good mechanical and biocompatible properties, can adapt to culture with cartilage bone cells and compound with growth factor and small molecular or peptides, it can be used to repair cartilage simultaneously.

The invention discloses a method for preparing collagen-II aquagel for inducing chondrogenic differentiation of stem cells. The method comprises the steps: firstly, synthesizing photo-crosslinking collagen II, which has photo-crosslinking performance and keeps tri-helical conformation of collagen II complete, through an amidation reaction between lateral-chain lysine epsilon-amino of the collagenII and methacrylic anhydride; and then, initiating the polymerization crosslinking of the photo-crosslinking collagen II under the action of a photoinitiator so as to form the collagen-II aquagel withcertain mechanical strength and adjustable mono-components. The collagen-II aquagel is used for providing a biological bionic differentiation microenvironment for the stem cells.

The invention discloses application of an epidermal growth factor receptor blocking agent to preparation of a medicine for treating osteoarthritis. The epidermal growth factor receptor blocking agent is gefitinib or erlotinib. Gefitinib / chitosan microspheres are favorable in dispersion and smooth in surface, has the drug slow-release performance and mouse articular cavity biocompatibility, can effectively relieve mouse osteoarthritis, promotes the expression of mouse osteoarthritis knee joint collagen II and inhibits the expression of MMP-13; besides, gefitinib is a clinical medicine, is widely used for treating the non-small cell lung cancer, and obtains excellent clinical curative effects, so that the extremely high economic cost and the long research and development period, which are required for medicine research and development, are reduced and shortened respectively; and owing to the dosing way of sustained-release medicine delivery, the local medicine concentration can be improved while corresponding side effects caused by whole-body medicine application are reduced, and a clinical application prospect is achieved.

The present invention relates to antibodies against human collagen II, polypeptides and polynucleotides encoding human collagen II antibodies or fragments thereof, and methods of making and using the foregoing.

The combination of a first binding site specifically binding to a target associated with an eye disease and a second binding site specifically binding to a target influencing the retention in the eye a multispecific binder provides for improved intravitreal retention compared to a monospecific binder. The second binding site specifically binds to a compound / molecules found in the extracellular matrix (ECM) in vitreous humor / retina. This compound of the extracellular matrix has to be present in amounts allowing a sufficient loading / dose of the drug to be bound. It has been found that collagen, especially collagen II, is a suitable compound in the ECM in the vitreous humor for this purpose. Thus, herein is reported a multispecific binder comprising a first binding site specifically binding to a therapeutic ocular target, and a second binding site specifically binding to collagen II.

The invention discloses a method for adjusting isoelectric points of collagen II. The method includes the steps of 1), weighing a certain amount of the collagen II with a three-screws structure and with telopeptide removed, adding 100-1000 times the weight of 0.05-0.5mol / L of an organic acid solution, allowing to dissolve completely by means of stirring, performing displacement of solution with an ultrafiltration method, adding an alkaline solution with pH value being 7.5-11 during ultrafiltration, and continuously performing ultrafiltration till difference value between a permeate solution pH and the added alkaline solution pH is lower than 0.2; 2), feeding the alkaline solution of the collagen II to a constant-temperature reaction kettle, controlling the temperature of the solution in the reaction kettle to be 10-40DEG C, continuously adding an acid aqueous solution to the reaction kettle, controlling total adding amount of acid anhydride to be 0.01-1 times the weight of the collagen II, and adopting the alkaline solution with the pH value being 12-14 to control pH of the reaction solution to be maintained in pH 7.5-11; 3), adding an acid diluting solution to the solution prepared in the step 2) till flocky precipitate appears in the solution, recording the pH value of the solution during settling, subjecting the solution to centrifugal treatment and collecting the precipitate; 4), subjecting the precipitate to freeze drying.

The invention belongs to the field of polymer functional materials, specifically zwitterionic hydrogel capable of recruiting type II collagen and its preparation method and application. The zwitterionic hydrogel realizes the chemistry of type II collagen-binding polypeptide WYRGRL by introducing co-polymerized active ester monomers. Modified, prepared by UV cross-linking. This hydrogel can specifically bind type II collagen in cartilage components. When co-cultured with chondrocytes or bone marrow mesenchymal stem cells, it can preferentially capture a large amount of type II collagen in situ, thereby promoting the process of cartilage differentiation and improving hydraulic coagulation. Gum cartilage repair ability. At the same time, the lubricity provided by the zwitterionic monomer can avoid the wear of the hydrogel during high-shear motion. This zwitterionic hydrogel with II collagen recruitment function has broad application prospects in bone tissue engineering.

The invention discloses a special extraction device for main ingredient collagen II of natural cartilage matrix. The special extraction device comprises an incubator, a centrifugal device arranged in the incubator, and a control system used for controlling the temperature in the incubator and the action of the centrifugal device, wherein the centrifugal device comprises a centrifugal machine, a container device installed on the centrifugal machine, a liquid adding system used for adding a reagent into the container device, a filtering and liquid discharging system used for discharging waste liquid in the container device, and a stirring system used for stirring the reagent. The special extraction device for main ingredient collagen II of natural cartilage matrix disclosed by the invention can be used for automatically completing the extraction of the main ingredient collagen II of the natural cartilage matrix, effectively saving the manpower, reducing the production cost and improving the production efficiency.